Comparative efficacy of long‐term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis

Several antibiotic treatments aiming to prevent spontaneous bacterial peritonitis (SBP) in cirrhotic patients with low‐protein content in ascitic fluid have been tested; however, there are limited data on the comparative efficacy of these regimens. We assessed their comparative efficacy through a network meta‐analysis and using GRADE criteria to appraise quality of evidence.

• Publication year

  2019

• Venue

  Liver international (Print)

• Publication date

  2019-04-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/liv.14109PMID 30920712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis.

  2019cited by this paper
• Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites

  2018cited by this paper
• Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial

  2018cited by this paper
• Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.

  2018cited by this paper
• Infections complicating cirrhosis

  2018cited by this paper
• Systematic review with meta‐analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis

  2017cited by this paper
• Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.

  2017cited by this paper
• Comparative Efficacy of Colonoscope Distal Attachment Devices in Increasing Rates of Adenoma Detection: A Network Meta‐analysis

  2017cited by this paper
• Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study

  2016cited by this paper
• Antibiotic prophylaxis in cirrhosis: Good and bad

  2016cited by this paper
• A randomized controlled study of trimethoprim‐sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients

  2014cited by this paper
• A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

  2014cited by this paper
• Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial

  2012cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.

  2011cited by this paper
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

  2010cited by this paper
• Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.

  2010cited by this paper
• Management of adult patients with ascites due to cirrhosis: An update

  2009cited by this paper
• Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis.

  2009cited by this paper
• Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.

  2008cited by this paper
• Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

  2007cited by this paper
• Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites

  2005cited by this paper
• Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club

  2005cited by this paper
• Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis.

  2005cited by this paper
• Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis

  2002cited by this paper
• Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.

  1999cited by this paper
• Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.

  1998cited by this paper
• Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin

  1997cited by this paper
• Trimethoprim-Sulfamethoxazole for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhosis

  1995cited by this paper
• Ciprofloxacin and long‐term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial

  1995cited by this paper
• A prospective study of bacterial infections in patients with cirrhosis.

  1993cited by this paper
• Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.

  1992cited by this paper

• Soluble Cluster of Differentiation 14 as a Prognostic Marker in Decompensated Cirrhosis With Water Retention.

  2025cites this paper
• The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.

  2025cites this paper
• Mise au point sur le bon usage des fluoroquinolones – Actualisation 2025 de la SPILF et du GPIP

  2025cites this paper
• Chronic exposure to ampicillin alters lung microbial composition in laboratory rat

  2023cites this paper
• Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota

  2023cites this paper
• Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

  2023cites this paper
• Palliative clinical trials in advanced chronic liver Disease: challenges and opportunities.

  2023cites this paper
• Mastering core recommendations during HEPAtology ROUNDS in advanced chronic liver disease.

  2022cites this paper
• Prophylaxis against spontaneous bacterial peritonitis: Too much or too little?

  2022cites this paper
• Evidence-Based Commentary: Antibiotics for Prophylaxis of Spontaneous Bacterial Peritonitis

  2022cites this paper
• Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure

  2022cites this paper
• Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents

  2021cites this paper
• Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases

  2021cites this paper
• The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.

  2021cites this paper
• Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF).

  2021cites this paper
• Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis

  2020cites this paper
• Bacterial infections in cirrhosis: a narrative review and key points for clinical practice

  2020cites this paper
• Procalcitonin and C-reactive protein in the diagnosis of spontaneous bacterial peritonitis

  2020cites this paper
• Letter: long‐term abdominal drains in refractory ascites—evolving concept of palliative care in decompensated cirrhosis. Authors' reply

  2020cites this paper
• Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis

  2020cites this paper
• Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis.

  2020cites this paper
• Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects

  2019cites this paper
• TCRM_A_205328 1383..1391

  2019cites this paper
• Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art

  2019cites this paper